BlackRock’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $139M | Buy |
8,193,085
+347,564
| +4% | +$5.55M | ﹤0.01% | 2022 |
|
|
2026
Q1 | $116M | Sell |
7,845,521
-82,608
| -1% | -$1.21M | ﹤0.01% | 2003 |
|
|
2025
Q4 | $126M | Buy |
7,928,129
+479,271
| +6% | +$6.79M | ﹤0.01% | 1955 |
|
|
2025
Q3 | $82.3M | Sell |
7,448,858
-244,298
| -3% | -$2.67M | ﹤0.01% | 2222 |
|
|
2025
Q2 | $65.2M | Sell |
7,693,156
-1,066,232
| -12% | -$8.55M | ﹤0.01% | 2302 |
|
|
2025
Q1 | $70.4M | Sell |
8,759,388
-192,297
| -2% | -$1.56M | ﹤0.01% | 2198 |
|
|
2024
Q4 | $80.4M | Sell |
8,951,685
-114,246
| -1% | -$932K | ﹤0.01% | 2201 |
|
|
2024
Q3 | $66.5M | Sell |
9,065,931
-206,231
| -2% | -$1.28M | ﹤0.01% | 2311 |
|
|
2024
Q2 | $52.9M | Buy |
9,272,162
+609,184
| +7% | +$3.21M | ﹤0.01% | 2377 |
|
|
2024
Q1 | $43.4M | Sell |
8,662,978
-258,071
| -3% | -$1.75M | ﹤0.01% | 2521 |
|
|
2023
Q4 | $80.2M | Buy |
8,921,049
+508,652
| +6% | +$4.19M | ﹤0.01% | 2211 |
|
|
2023
Q3 | $65.4M | Buy |
8,412,397
+79,363
| +1% | +$776K | ﹤0.01% | 2246 |
|
|
2023
Q2 | $80.7M | Buy |
8,333,034
+429,319
| +5% | +$4.46M | ﹤0.01% | 2189 |
|
|
2023
Q1 | $86.6M | Sell |
7,903,715
-266,803
| -3% | -$2.35M | ﹤0.01% | 2096 |
|
|
2022
Q4 | $35.3M | Buy |
8,170,518
+457,463
| +6% | +$2.65M | ﹤0.01% | 2700 |
|
|
2022
Q3 | $58M | Sell |
7,713,055
-98,688
| -1% | -$854K | ﹤0.01% | 2332 |
|
|
2022
Q2 | $78.5M | Buy |
7,811,743
+5,984,327
| +327% | +$66.9M | ﹤0.01% | 2187 |
|
|
2022
Q1 | $22.6M | Buy |
1,827,416
+6,677
| +0.4% | +$103K | ﹤0.01% | 3100 |
|
|
2021
Q4 | $41.6M | Buy |
1,820,739
+918,076
| +102% | +$21.8M | ﹤0.01% | 2776 |
|
|
2021
Q3 | $20M | Buy |
902,663
+291,672
| +48% | +$4.63M | ﹤0.01% | 3278 |
|
|
2021
Q2 | $7.92M | Sell |
610,991
-491,997
| -45% | -$6.27M | ﹤0.01% | 3731 |
|
|
2021
Q1 | $14.3M | Sell |
1,102,988
-27,341
| -2% | -$397K | ﹤0.01% | 3367 |
|
|
2020
Q4 | $15.6M | Sell |
1,130,329
-95,955
| -8% | -$1.4M | ﹤0.01% | 3138 |
|
|
2020
Q3 | $18.1M | Buy |
1,226,284
+50,458
| +4% | +$731K | ﹤0.01% | 2914 |
|
|
2020
Q2 | $19.1M | Buy |
1,175,826
+244,313
| +26% | +$3.91M | ﹤0.01% | 2822 |
|
|
2020
Q1 | $13.5M | Buy |
931,513
+62,202
| +7% | +$1.1M | ﹤0.01% | 2823 |
|
|
2019
Q4 | $17.6M | Sell |
869,311
-41,849
| -5% | -$385K | ﹤0.01% | 2953 |
|
|
2019
Q3 | $4.87M | Sell |
911,160
-10,265
| -1% | -$62.1K | ﹤0.01% | 3488 |
|
|
2019
Q2 | $6.06M | Buy |
921,425
+28,129
| +3% | +$179K | ﹤0.01% | 3472 |
|
|
2019
Q1 | $5.81M | Sell |
893,296
-67,489
| -7% | -$448K | ﹤0.01% | 3355 |
|
|
2018
Q4 | $6.55M | Sell |
960,785
-22,100
| -2% | -$127K | ﹤0.01% | 3294 |
|
|
2018
Q3 | $6.53M | Buy |
982,885
+2,546
| +0.3% | +$14.3K | ﹤0.01% | 3413 |
|
|
2018
Q2 | $5.52M | Sell |
980,339
-64,782
| -6% | -$361K | ﹤0.01% | 3475 |
|
|
2018
Q1 | $5.42M | Buy |
1,045,121
+325,408
| +45% | +$1.74M | ﹤0.01% | 3395 |
|
|
2017
Q4 | $3.26M | Buy |
+719,713
| New | +$4M | ﹤0.01% | 3566 |
|
Other funds holding AUPH
TCM
NMC
BlackRock's AUPH Position: Q2 2026 in Review
BlackRock increased its Aurinia Pharmaceuticals (AUPH) stake by 4.4% in Q2 2026, buying an estimated $5.55M and bringing the position to 8,193,085 shares worth $139M. The position accounts for ﹤0.01% of the portfolio, ranked #2022.
BlackRock first reported a position in AUPH in Q4 2017 and has held it in 35 quarters since. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.
- BlackRock held 8,193,085 shares of Aurinia Pharmaceuticals worth $139M as of Q2 2026.
- BlackRock bought 347,564 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $5.55M.
- Aurinia Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2022 holding.
- BlackRock first reported a position in Aurinia Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.